The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant
The number of pregnant women with cancer is on the rise. These patients and their providers encounter complex medical management decisions. Standard-of-care systemic therapy and radiological imaging can impair fetal development and affect viability. Conversely, insufficient monitoring and treatment...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2022/9412201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564638026301440 |
|---|---|
| author | Stacey A. Cohen Anup Kasi Nicole Hook Michael Krainock Griffin Budde Allyson Koyen Malashevich Jeffrey Meltzer Russ Jelsema Perry Olshan Paul R. Billings Alexey Aleshin Andrew S. Poklepovic |
| author_facet | Stacey A. Cohen Anup Kasi Nicole Hook Michael Krainock Griffin Budde Allyson Koyen Malashevich Jeffrey Meltzer Russ Jelsema Perry Olshan Paul R. Billings Alexey Aleshin Andrew S. Poklepovic |
| author_sort | Stacey A. Cohen |
| collection | DOAJ |
| description | The number of pregnant women with cancer is on the rise. These patients and their providers encounter complex medical management decisions. Standard-of-care systemic therapy and radiological imaging can impair fetal development and affect viability. Conversely, insufficient monitoring and treatment can lead to cancer progression, compromising the health of the patient. Personalized and tumor-informed circulating tumor DNA (ctDNA) testing (Signatera™, bespoke mPCR NGS assay) is a validated, noninvasive blood test that can accurately assess cancer progression and tumor response to treatment ahead of radiological imaging, across solid tumors. In this case series of four patients, we explore the clinical utility of longitudinal ctDNA testing in the medical management of pregnant patients with solid tumors, to aid in informed decision-making for patients and providers. |
| format | Article |
| id | doaj-art-d159d32c0baa423397d54d72db0ae461 |
| institution | Kabale University |
| issn | 2090-6692 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Obstetrics and Gynecology |
| spelling | doaj-art-d159d32c0baa423397d54d72db0ae4612025-02-03T01:10:35ZengWileyCase Reports in Obstetrics and Gynecology2090-66922022-01-01202210.1155/2022/9412201The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become PregnantStacey A. Cohen0Anup Kasi1Nicole Hook2Michael Krainock3Griffin Budde4Allyson Koyen Malashevich5Jeffrey Meltzer6Russ Jelsema7Perry Olshan8Paul R. Billings9Alexey Aleshin10Andrew S. Poklepovic11University of WashingtonUniversity of Kansas Medical CenterNateraNateraNateraNateraNateraNateraNateraNateraNateraVCU Health System Massey Cancer CenterThe number of pregnant women with cancer is on the rise. These patients and their providers encounter complex medical management decisions. Standard-of-care systemic therapy and radiological imaging can impair fetal development and affect viability. Conversely, insufficient monitoring and treatment can lead to cancer progression, compromising the health of the patient. Personalized and tumor-informed circulating tumor DNA (ctDNA) testing (Signatera™, bespoke mPCR NGS assay) is a validated, noninvasive blood test that can accurately assess cancer progression and tumor response to treatment ahead of radiological imaging, across solid tumors. In this case series of four patients, we explore the clinical utility of longitudinal ctDNA testing in the medical management of pregnant patients with solid tumors, to aid in informed decision-making for patients and providers.http://dx.doi.org/10.1155/2022/9412201 |
| spellingShingle | Stacey A. Cohen Anup Kasi Nicole Hook Michael Krainock Griffin Budde Allyson Koyen Malashevich Jeffrey Meltzer Russ Jelsema Perry Olshan Paul R. Billings Alexey Aleshin Andrew S. Poklepovic The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant Case Reports in Obstetrics and Gynecology |
| title | The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant |
| title_full | The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant |
| title_fullStr | The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant |
| title_full_unstemmed | The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant |
| title_short | The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant |
| title_sort | utility of circulating tumor dna ctdna monitoring in cancer patients who are pregnant or planning to become pregnant |
| url | http://dx.doi.org/10.1155/2022/9412201 |
| work_keys_str_mv | AT staceyacohen theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT anupkasi theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT nicolehook theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT michaelkrainock theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT griffinbudde theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT allysonkoyenmalashevich theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT jeffreymeltzer theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT russjelsema theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT perryolshan theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT paulrbillings theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT alexeyaleshin theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT andrewspoklepovic theutilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT staceyacohen utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT anupkasi utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT nicolehook utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT michaelkrainock utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT griffinbudde utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT allysonkoyenmalashevich utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT jeffreymeltzer utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT russjelsema utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT perryolshan utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT paulrbillings utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT alexeyaleshin utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant AT andrewspoklepovic utilityofcirculatingtumordnactdnamonitoringincancerpatientswhoarepregnantorplanningtobecomepregnant |